HC Wainwright Has Pessimistic Outlook of PHIO Q2 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Phio Pharmaceuticals in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings per share of ($0.35) for the quarter, down from their previous estimate of ($0.23). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.40) EPS and FY2027 earnings at ($0.63) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Trading Up 0.9%

Shares of PHIO stock opened at $1.08 on Tuesday. Phio Pharmaceuticals has a 1 year low of $0.81 and a 1 year high of $4.19. The firm’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.25. The firm has a market capitalization of $12.55 million, a P/E ratio of -0.74 and a beta of 0.84.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10).

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Cetera Investment Advisers grew its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,500 shares of the company’s stock after buying an additional 9,000 shares during the quarter. Cetera Investment Advisers owned 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.